Comment on EPITHET: failed chance or new hope? Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
Importance: Intravenous alteplase reduces disability after ischemic stroke in patients 4.5 to 9 hour...
Many thanks for giving us the opportunity to reply to the letter in reference to our review ‘The exa...
when using coregistration techniques to determine the presence of mismatch at study entry, alteplase...
Alteplase was non-significantly associated with lower infarct growth and significantly associated wi...
to test whether alteplase given 3-6 h after stroke onset promotes reperfusion and attenuates infarct...
the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double...
Background and Purpose - Two phase 2 studies of alteplase in acute ischemic stroke 3 to 6 hours afte...
Background and Purpose—: The Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospe...
C1 - Journal Articles RefereedBACKGROUND: Early administration of intravenous recombinant tissue pla...
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasmi...
BACKGROUND: Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemi...
Reperfusion and recanalization have both been used as surrogate markers of clinical outcome in trial...
Importance: Intravenous alteplase reduces disability after ischemic stroke in patients 4.5 to 9 hour...
BACKGROUND:Stroke thrombolysis with alteplase is currently recommended 0-4·5 h after stroke onset. W...
Intravenous thrombolysis with alteplase (Genentech; San Francisco, CA) is the only FDA approved trea...
Importance: Intravenous alteplase reduces disability after ischemic stroke in patients 4.5 to 9 hour...
Many thanks for giving us the opportunity to reply to the letter in reference to our review ‘The exa...
when using coregistration techniques to determine the presence of mismatch at study entry, alteplase...
Alteplase was non-significantly associated with lower infarct growth and significantly associated wi...
to test whether alteplase given 3-6 h after stroke onset promotes reperfusion and attenuates infarct...
the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospective, randomized, double...
Background and Purpose - Two phase 2 studies of alteplase in acute ischemic stroke 3 to 6 hours afte...
Background and Purpose—: The Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) was a prospe...
C1 - Journal Articles RefereedBACKGROUND: Early administration of intravenous recombinant tissue pla...
Rationale: Alteplase is the only approved thrombolytic agent for acute stroke. An alternative plasmi...
BACKGROUND: Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemi...
Reperfusion and recanalization have both been used as surrogate markers of clinical outcome in trial...
Importance: Intravenous alteplase reduces disability after ischemic stroke in patients 4.5 to 9 hour...
BACKGROUND:Stroke thrombolysis with alteplase is currently recommended 0-4·5 h after stroke onset. W...
Intravenous thrombolysis with alteplase (Genentech; San Francisco, CA) is the only FDA approved trea...
Importance: Intravenous alteplase reduces disability after ischemic stroke in patients 4.5 to 9 hour...
Many thanks for giving us the opportunity to reply to the letter in reference to our review ‘The exa...
when using coregistration techniques to determine the presence of mismatch at study entry, alteplase...